Quanterix Corporation (QTRX)
| Market Cap | 135.67M -42.2% |
| Revenue (ttm) | 144.98M +6.8% |
| Net Income | -104.19M |
| EPS | -2.33 |
| Shares Out | 47.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,339,305 |
| Open | 2.915 |
| Previous Close | 2.910 |
| Day's Range | 2.810 - 2.985 |
| 52-Week Range | 2.560 - 8.770 |
| Beta | 1.15 |
| Analysts | Hold |
| Price Target | 4.00 (+38.89%) |
| Earnings Date | May 6, 2026 |
About QTRX
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, s... [Read more]
Financial Performance
In 2025, Quanterix's revenue was $138.90 million, an increase of 1.07% compared to the previous year's $137.42 million. Losses were -$107.15 million, 178.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $4.0, which is an increase of 38.89% from the latest price.
News
Quanterix announces CFO transition
Quanterix (QTRX) “announced that Vandana Sriram, its CFO will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026,…
Quanterix Announces Planned Transition of Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that V...
Quanterix price target lowered to $4 from $7 at TD Cowen
TD Cowen lowered the firm’s price target on Quanterix (QTRX) to $4 from $7 and keeps a Hold rating on the shares. The firm said 1Q was largely in line…
Lucent Diagnostics announces collaboration with Tempus AI
Lucent Diagnostics, a brand of Quanterix Corporation (QTRX), announced a collaboration with Tempus AI (TEM) to broaden access to a novel blood-based biomarker panel designed to improve detection accur...
Quanterix reports Q1 EPS (37c), consensus (62c)
Reports Q1 revenue $36.4M, consensus $36.84M. The company said, “”We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we…
Quanterix affirms 2026 revenue outlook $169M-$174M
The company said, “Quanterix (QTRX) is reaffirming its guidance for 2026. The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutica...
Quanterix Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 20% year-over-year to $36.4 million, with strong diagnostics partner growth but declines in core segments. Strategic investments in commercial effectiveness and diagnostics are expected to drive a stronger second half, with cash flow breakeven targeted by year-end.
Quanterix Releases Financial Results for the First Quarter of 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ...
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading ...
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
Quanterix price target lowered to $4 from $8 at Canaccord
Canaccord lowered the firm’s price target on Quanterix (QTRX) to $4 from $8 and keeps a Hold rating on the shares. The firm updated its model ahead of Q1 results.
Quanterix, PreludeDX highlights AidaBREAST multi-omic assay
PreludeDx and Quanterix (QTRX) Corporation highlighted that AidaBREAST, a multi-omic assay made to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breas...
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregiona...
Quanterix debuts Content Innovation Engine at AACR 2026
Quanterix (QTRX) Corporation announced plans to debut its Content Innovation Engine at the American Association for Cancer Research, AACR, Annual Meeting 2026. Built on the integration of Akoya Biosci...
Quanterix Debuts Content Innovation Engine at AACR 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeti...
Quanterix Corporation Announces Date of 2026 Annual Meeting
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Co...
Quanterix Transcript: Leerink Global Healthcare Conference 2026
New leadership is driving a strategic transformation, emphasizing diagnostics as a growth engine and leveraging the Akoya acquisition for diversification. Financial discipline has resulted in strong recurring revenue and margin recovery, while a differentiated diagnostics test and focused product development position the company for sustainable growth.
Quanterix Transcript: TD Cowen 46th Annual Health Care Conference
Management outlined a strategy focused on diagnostics growth, especially in Alzheimer's, leveraging a strong recurring revenue base and successful Akoya integration. Financial performance exceeded expectations, with robust consumables demand and margin improvements. A comprehensive diagnostics plan and further international expansion are key priorities for future growth.
Quanterix Earnings Call Transcript: Q4 2025
Q4 2025 revenue rose 25% year-over-year to $43.9 million, with strong academic demand and expanded diagnostics partnerships. 2026 guidance targets $169–$174 million revenue, cash flow breakeven in H2, and continued investment in Alzheimer's diagnostics and assay innovation.
Quanterix reports Q4 EPS (49c) vs. (30c) last year
Reports Q4 revenue $43.9M, consensus $38.0M. “I am thrilled to be joining Quanterix (QTRX) at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, Presiden...
Quanterix sees FY26 revenue $169M-$174M, consensus $168.8M
Quanterix (QTRX) is issuing its initial guidance for 2026. The Company expects revenues of $169 to $174 million, GAAP gross margin of 45-49%, and adjusted gross margin (non-GAAP) of 49%…
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on...
Quanterix to Participate in Upcoming Investor Conferences
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...